Pharmacotherapy for Alzheimer's disease: 2002.
The intensity of interest in therapy for Alzheimer's disease (AD) has accelerated with each passing year. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined long-term therapy as well as different aspects of the symptomatology of AD. Breakthroughs in the basic science of AD has led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach in which the amyloid-beta protein itself was used as the immunizing agent was discontinued after unexpected toxicity occurred. Other areas of investigation with disappointing results such as estrogen replacement therapy and antiinflammatory approaches are discussed. Several other potential therapeutic agents are also reviewed.
Knopman
David
D
Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. knopman@mayo.edu
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology / Q000523:psychology; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans
D002800:Cholinesterase Inhibitors